Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer

This publication has 23 references indexed in Scilit:

• Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts
  Clinical Breast Cancer, 2002
• Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
  JNCI Journal of the National Cancer Institute, 2002
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• The urokinase plasminogen activator system as a novel target for tumour therapy
  Fibrinolysis and Proteolysis, 2000
• Do we need prognostic factors in nodal-negative breast cancer?: Arbiter:
  European Journal Of Cancer, 2000
• Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse
  Breast Cancer Research and Treatment, 1999
• The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
  The International Journal of Cell Cloning, 1998
• Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
  JNCI Journal of the National Cancer Institute, 1996
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994
• Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast Cancer
  New England Journal of Medicine, 1992